SE449753B - Mukopolysackaridkomposition med reglerande verkan pa koagulation, lekemedel innehallande densamma samt forfarande for framstellning derav - Google Patents

Mukopolysackaridkomposition med reglerande verkan pa koagulation, lekemedel innehallande densamma samt forfarande for framstellning derav

Info

Publication number
SE449753B
SE449753B SE7909087A SE7909087A SE449753B SE 449753 B SE449753 B SE 449753B SE 7909087 A SE7909087 A SE 7909087A SE 7909087 A SE7909087 A SE 7909087A SE 449753 B SE449753 B SE 449753B
Authority
SE
Sweden
Prior art keywords
concentration
yin
fractions
units
mixture
Prior art date
Application number
SE7909087A
Other languages
English (en)
Swedish (sv)
Other versions
SE7909087L (sv
Inventor
J-C Lormeau
J Goulay
J Choay
Original Assignee
Choay Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR7831357A external-priority patent/FR2440376A1/fr
Priority claimed from FR7918873A external-priority patent/FR2461719A2/fr
Application filed by Choay Sa filed Critical Choay Sa
Publication of SE7909087L publication Critical patent/SE7909087L/xx
Publication of SE449753B publication Critical patent/SE449753B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8128—Antithrombin III
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Materials Engineering (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
SE7909087A 1978-11-06 1979-11-01 Mukopolysackaridkomposition med reglerande verkan pa koagulation, lekemedel innehallande densamma samt forfarande for framstellning derav SE449753B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7831357A FR2440376A1 (fr) 1978-11-06 1978-11-06 Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir
FR7918873A FR2461719A2 (fr) 1979-07-20 1979-07-20 Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir

Publications (2)

Publication Number Publication Date
SE7909087L SE7909087L (sv) 1980-05-07
SE449753B true SE449753B (sv) 1987-05-18

Family

ID=26220837

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7909087A SE449753B (sv) 1978-11-06 1979-11-01 Mukopolysackaridkomposition med reglerande verkan pa koagulation, lekemedel innehallande densamma samt forfarande for framstellning derav

Country Status (6)

Country Link
US (1) US4486420A (it)
JP (1) JPH03243601A (it)
DE (1) DE2944792C3 (it)
GB (1) GB2035349B (it)
IT (1) IT1126319B (it)
SE (1) SE449753B (it)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692435A (en) * 1978-11-06 1987-09-08 Choay, S.A. Mucopolysaccharide composition having a regulatory action on coagulation, medicament containing same and process of preparation
FR2478646A2 (fr) * 1980-03-20 1981-09-25 Choay Sa Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir
IL61201A (en) * 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
CA1171375A (en) * 1980-09-15 1984-07-24 Ulf P.F. Lindahl Oligosaccharides having selective anticoagulation activity
FR2503714B1 (fr) * 1981-04-10 1986-11-21 Choay Sa Procede d'obtention de mucopolysaccharides biologiquement actifs, de purete elevee, par depolymerisation de l'heparine
IT1163772B (it) * 1983-07-13 1987-04-08 Baldacci Lab Spa Oligosaccaridi eterogenei complessabili ed alfa-idosani ad attivita' terapeutica, procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2568774B2 (fr) * 1984-05-30 1989-05-19 Choay Sa Medicaments favorisant les proprietes d'ecoulement du sang et leur utilisation en therapeutique
CA1260461A (fr) * 1984-10-18 1989-09-26 Jean-Claude Lormeau Procede de preparation de compositions de mucopolysaccharides dotes d'une activite antithrombotique elevee
US4788307A (en) * 1986-04-30 1988-11-29 Choay S.A. Oligosaccharidic fractions devoid or practically devoid of antithrombotic activity
US4942156A (en) * 1986-08-20 1990-07-17 Hepar Industries, Inc. Low molecular weight heparin derivatives having improved anti-Xa specificity
US4745106A (en) * 1986-08-20 1988-05-17 Griffin Charles C Heparin derivatives having improved anti-Xa specificity
USRE38743E1 (en) 1990-06-26 2005-06-14 Aventis Pharma S.A. Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events
GB9206291D0 (en) * 1992-03-23 1992-05-06 Cancer Res Campaign Tech Oligosaccharides having growth factor binding affinity
DK0946185T4 (da) * 1996-11-27 2010-08-30 Aventis Pharma Inc Farmaceutisk præparat, som omfatter en forbindelse med anti-Xa-aktivitet og en blodpladeaggregations antagonistforbindelse
EP0986581A1 (en) * 1997-06-06 2000-03-22 Hamilton Civic Hospitals Research Development, Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
EP1190364A2 (en) 1999-04-23 2002-03-27 Massachusetts Institute Of Technology System and method for polymer notation
MXPA02000142A (es) * 1999-06-30 2003-07-21 Hamilton Civic Hospitals Res Composiciones de heparina que inhiben los factores de coagulacion asociados con el coagulo.
CN1473061A (zh) * 2000-09-08 2004-02-04 ���ܶ�����ҽԺ�о���չ���޹�˾ 抗血栓形成的组合物
AU2009250803A1 (en) * 2008-05-20 2009-11-26 Crystal Clear Partnership Separation of polysaccharides by charge density gradient

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1042001A (en) * 1973-04-13 1978-11-07 Choay S.A. Mixed heparin salts
SE431218B (sv) * 1976-03-05 1984-01-23 Kabi Ab Forfarande for rening av heparin
IT1083903B (it) * 1977-08-09 1985-05-25 Lobo Srl Oligo-eteropolisaccaridi con attivita' eparinosimili,procedimento per il loro ottenimento e relative composizioni terapeutiche
US4122250A (en) * 1977-08-22 1978-10-24 Gottfried Schmer Separation of high-activity heparin by affinity chromatography
US4175182A (en) * 1978-07-03 1979-11-20 Research Corporation Separation of high-activity heparin by affinity chromatography on supported protamine
CA1136620A (en) * 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
HU177887B (en) * 1979-03-21 1982-01-28 Richter Gedeon Vegyeszet Process for preparing a raw material containing heparin
US4281108A (en) * 1980-01-28 1981-07-28 Hepar Industries, Inc. Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained

Also Published As

Publication number Publication date
SE7909087L (sv) 1980-05-07
DE2944792C2 (it) 1994-04-14
IT1126319B (it) 1986-05-21
DE2944792C3 (de) 1994-04-14
IT7927064A0 (it) 1979-11-06
GB2035349A (en) 1980-06-18
DE2944792A1 (de) 1980-05-14
JPH03243601A (ja) 1991-10-30
GB2035349B (en) 1983-05-11
US4486420A (en) 1984-12-04

Similar Documents

Publication Publication Date Title
US4692435A (en) Mucopolysaccharide composition having a regulatory action on coagulation, medicament containing same and process of preparation
SE449753B (sv) Mukopolysackaridkomposition med reglerande verkan pa koagulation, lekemedel innehallande densamma samt forfarande for framstellning derav
DK173385B1 (da) Analogifremgangsmåde til fremstilling af oligosaccharidfraktioner eller oligosaccharider med specifik anti-Xa-aktivitet
JPH0323528B2 (it)
DE3880577T2 (de) Heparinderivate, verfahren zu deren herstellung und verwendung fuer pharmazeutische zwecke.
Young et al. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins
US4500519A (en) Mucopolysaccharides having biological properties, preparation and method of use
Linhardt et al. Homogeneous, structurally defined heparin-oligosaccharides with low anticoagulant activity inhibit the generation of the amplification pathway C3 convertase in vitro.
JPH04503950A (ja) 平滑筋細胞増殖のインヒビターとしてのヘパリン断片
CN103209997B (zh) 高纯度肝素及其制备方法
Mulloy et al. Assays and reference materials for current and future applications of heparins
USRE35770E (en) Oligosaccharides having anti-Xa activity and pharmaceutical compositions containing them
Zhu et al. Heparin contamination and issues related to raw materials and controls
Suda et al. Structural characterization of heparin's binding domain for human platelets
Andermann et al. The influence of the route of administration on the bioavailability of an endogenous macromolecule: chondroitin sulphate (CSA)
Wan et al. Renal contribution to overall metabolism of drugs III: Metabolism of p‐aminobenzoic acid
US4067964A (en) Antihemophilic agent and process for its manufacture
EP2283045A1 (en) Separation of polysaccharides by charge density gradient
US20220096530A1 (en) Safe bovine heparin, preparation method, and application
Hanin et al. Acetylcholine and choline in human plasma and red blood cells: a gas chromatograph mass spectrometric evaluation
Ayotte et al. Influence of variations in the chemical structure of heparin on its anticoagulant and anti-factor Xa activities
Hurst et al. Partition techniques for isolation and fractionation of urinary glycosaminoglycans
Rădulescu et al. The in vitro release profiles of nimesulide from oral solid dosage forms, in compendial and modified physiological media
Kretchmer et al. Cellular mechanisms of protein metabolism in the nephron: V. The intracellular partition and the incorporation into protein of intravenously injected L-lysine
CN113230164A (zh) 一种肉苁蓉鳞茎提取物的制备方法及改善透皮吸收效率中的应用、及经皮吸收效率检测方法

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 7909087-4

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 7909087-4

Format of ref document f/p: F